1. Home
  2. HYPR vs OKYO Comparison

HYPR vs OKYO Comparison

Compare HYPR & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

HOLD

Current Price

$0.86

Market Cap

83.2M

Sector

Health Care

ML Signal

HOLD

Logo OKYO Pharma Limited

OKYO

OKYO Pharma Limited

HOLD

Current Price

$1.45

Market Cap

71.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYPR
OKYO
Founded
2014
2007
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.2M
71.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
HYPR
OKYO
Price
$0.86
$1.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$2.03
★ $8.33
AVG Volume (30 Days)
★ 875.4K
67.3K
Earning Date
11-09-2026
07-20-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 23.21
N/A
EPS
N/A
★ N/A
Revenue
★ $13,563,000.00
N/A
Revenue This Year
$49.18
N/A
Revenue Next Year
$29.74
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 5.22
N/A
52 Week Low
$0.75
$1.26
52 Week High
$2.22
$3.20

Technical Indicators

Market Signals
Indicator
HYPR
OKYO
Relative Strength Index (RSI) 51.43 50.98
Support Level $0.75 $1.29
Resistance Level $1.39 $1.72
Average True Range (ATR) 0.07 0.09
MACD 0.01 0.01
Stochastic Oscillator 35.68 62.29

Price Performance

Historical Comparison
HYPR
OKYO

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.

About OKYO OKYO Pharma Limited

OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.

Share on Social Networks: